Stockreport

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Sangamo Therapeutics, Inc.  (SGMO) 
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sangamo.com
PDF - Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets- Sangamo to receive a $2 [Read more]